JMJason C. Mixdorf

Jason C. Mixdorf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jason C. Mixdorf has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-destructive luminescence and PET imaging to monitor tissue microenvironment in microphysiological systems during brain metastasis using dissociated cerebral organoids

    by Catherine Reed-McBain, Rithvik V Turaga, Seth R T Zima, Janmesh Patel, Anderson Weber Faletti Cunha, Jason Mixdorf, Lauren E Wehner, Jonathan W Engle, Reinier Hernandez, Stevens K Rehen, et al.

    During brain metastasis, tumor cells interact with the surrounding stroma, including neurons and astrocytes, to create a tumor-promoting microenvironment. However, the molecular and cellular factors driving tumor-neural stroma interactions remain unclear. Here, we developed a co-culture model of metastatic melanoma by combining metastatic melanoma cells with dissociated human iPSC-derived cerebral organoids, consisting of neurons and astrocytes, in a microfluidic device. We cultured these astrocytes and neurons in a 3D hydrogel that contained a domain with metastatic melanoma cells. This approach generated a spatially organized co-culture system with no physical boundary between the tumor and stromal compartments. Then, we leveraged several imaging modalities to study tumor-stroma interactions and changes in the microenvironment. Using non-destructive, luminescence-based methods, we spatially resolved changes in cell viability, metabolite concentration, and other biochemical parameters. We also used luminescence to analyze the effect of radionuclides on tumor cell viability and used PET imaging to monitor their diffusion across the system.


  • Open Access

    Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

    by Gihan S. Gunaratne, Joseph P. Gallant, Kendahl L. Ott, Payson L. Broome, Sasha Celada, Jayden L. West, Jason C. Mixdorf, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Eszter Boros, et al.

    Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.


  • Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [55Co]Co-NT-Sarcage as a Proof of Concept in a Murine Xenograft Model

    by Wilson Lin, German Oscar Fonseca Cabrera, Eduardo Aluicio-Sarduy, Todd E. Barnhart, Jason C. Mixdorf, Zibo Li, Zhanhong Wu, Jonathan W. Engle

    Cobalt-sarcophagine complexes exhibit high kinetic inertness under various stringent conditions, but there is limited literature on radiolabeling and in vivo positron emission tomography (PET) imaging using no carrier added 55Co. To fill this gap, this study first investigates the radiolabeling of DiAmSar (DSar) with 55Co, followed by stability evaluation in human serum and EDTA, pharmacokinetics in mice, and a direct comparison with [55Co]CoCl2 to assess differences in pharmacokinetics. Furthermore, the radiolabeling process was successfully used to generate the NTSR1-targeted PET agent [55Co]Co-NT-Sarcage (a DSar-functionalized SR142948 derivative) and administered to HT29 tumor xenografted mice. The [55Co]Co-DSar complex can be formed at 37 °C with purity and stability suitable for preclinical in vivo radiopharmaceutical applications, and [55Co]Co-NT-Sarcage demonstrated prominent tumor uptake with a low background signal. In a direct comparison with [64Cu]Cu-NT-Sarcage, [55Co]Co-NT-Sarcage achieved a higher tumor-to-liver ratio but with overall similar biodistribution profile. These results demonstrate that Sar would be a promising chelator for constructing Co-based radiopharmaceuticals including 55Co for PET and 58mCo for therapeutic applications.


  • Open Access

    A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy

    by Isidro Da Silva, Taylor R. Johnson, Jason C. Mixdorf, Eduardo Aluicio-Sarduy, Todd E. Barnhart, R. Jerome Nickles, Jonathan W. Engle, Paul A. Ellison

    Background: Radionuclides emitting Auger electrons (AEs) with low (0.02–50 keV) energy, short (0.0007–40 µm) range, and high (1–10 keV/µm) linear energy transfer may have an important role in the targeted radionuclide therapy of metastatic and disseminated disease. Erbium-165 is a pure AE-emitting radionuclide that is chemically matched to clinical therapeutic radionuclide 177Lu, making it a useful tool for fundamental studies on the biological effects of AEs. This work develops new biomedical cyclotron irradiation and radiochemical isolation methods to produce 165Er suitable for targeted radionuclide therapeutic studies and characterizes a new such agent targeting prostate-specific membrane antigen. Methods: Biomedical cyclotrons proton-irradiated spot-welded Ho(m) targets to produce 165Er, which was isolated via cation exchange chromatography (AG 50W-X8, 200–400 mesh, 20 mL) using alpha-hydroxyisobutyrate (70 mM, pH 4.7) followed by LN2 (20–50 µm, 1.3 mL) and bDGA (50–100 µm, 0.2 mL) extraction chromatography. The purified 165Er was radiolabeled with standard radiometal chelators and used to produce and characterize a new AE-emitting radiopharmaceutical, [165Er]PSMA-617. Results: Irradiation of 80–180 mg natHo targets with 40 µA of 11–12.5 MeV protons produced 165Er at 20–30 MBq·µA−1·h−1. The 4.9 ± 0.7 h radiochemical isolation yielded 165Er in 0.01 M HCl (400 µL) with decay-corrected (DC) yield of 64 ± 2% and a Ho/165Er separation factor of (2.8 ± 1.1) · 105. Radiolabeling experiments synthesized [165Er]PSMA-617 at DC molar activities of 37–130 GBq·µmol−1. Conclusions: A 2 h biomedical cyclotron irradiation and 5 h radiochemical separation produced GBq-scale 165Er suitable for producing radiopharmaceuticals at molar activities satisfactory for investigations of targeted radionuclide therapeutics. This will enable fundamental radiation biology experiments of pure AE-emitting therapeutic radiopharmaceuticals such as [165Er]PSMA-617, which will be used to understand the impact of AEs in PSMA-targeted radionuclide therapy of prostate cancer.


  • Alternative strategies for the synthesis of [11C]ER176 for PET imaging of neuroinflammation

    by Jason C. Mixdorf, Dhanabalan Murali, Yangchun Xin, Alexandra H. DiFilippo, Eduardo Aluicio-Sarduy, Todd E. Barnhart, Jonathan W. Engle, Paul A. Ellison, Bradley T. Christian


  • The Role of Trichloroacetimidate To Enable Iridium-Catalyzed Regio- and Enantioselective Allylic Fluorination: A Combined Experimental and Computational Study

    by Alexandre M. Sorlin, Jason C. Mixdorf, Madeline E. Rotella, Robert T. Martin, Osvaldo Gutierrez, Hien M. Nguyen

    Asymmetric allylic fluorination has proven to be a robust and efficient methodology with potential applications for the development of pharmaceuticals and practical synthesis for 18F-radiolabeling. Although there have been several efficient methods reported for the regioselective formation of allylic fluorides, there are few approaches available for the asymmetric synthesis of allyl fluorides. In 2011, initial studies toward a regioselective allylic fluorination reaction were undertaken in our laboratory. In our approach, allylic trichloroacetimidates were employed as electrophiles, Et3N•3HF as a nucleophilic fluoride source, and cyclooctadiene iridium chloride dimer, [Ir(COD)Cl]2, as a catalyst leading to the formation of branched allylic fluorides in good yields and excellent regioselectivities. In subsequent studies, racemic secondary allylic trichloroacetimidates were transformed to enantioenriched allylic fluorides catalyzed by a chiral bicyclo[3.3.0]octadiene (S,S)-ligated iridium complex. Herein, we report a detailed investigation that provides insight into the mechanism and origin of regio- and enantioselectivity of the iridium-catalyzed allylic fluorination. A synergistic computational and experimental study provides strong support for a dynamic kinetic asymmetric transformation (DYKAT) of racemic allylic trichloroacetimidate, leading to regio- and enantioselective allylic C-F bond formation. This combined study also highlights the dualistic nature of the trichloroacetimidate as a leaving/directing group and as a ligand to facilitate equilibration of diastereomeric π-allyl iridium intermediates via a pi-sigma-pi mechanism, leading to enantioenriched allylic fluorides.


  • Iridium-Catalyzed Radiosynthesis of Branched Allylic [18F]Fluorides

    by Jason C. Mixdorf, Alexandre M. Sorlin, David W. Dick, Hien M. Nguyen

    The rapid and operationally simple radiosynthesis of branched allylic [18F]fluorides bearing a variety of functional groups, via iridium-catalyzed nucleophilic substitution reaction utilizing allylic trichloroacetimidates and [18F]KF·Kryptofix[2.2.2] complex in 5–15 min at room temperature, is reported. The versatility of the allyl functional group of the resulting radiofluorinated products offers the benefit of being subsequently available for further functionalization.


  • Iridium-Catalyzed Enantioselective Fluorination of Racemic, Secondary Allylic Trichloroacetimidates

    by Qi Zhang, David P. Stockdale, Jason C. Mixdorf, Joseph J. Topczewski, Hien M. Nguyen

    The Ir-catalyzed enantioselective fluorination of racemic, branched allylic trichloroacetimidates with Et3N·3HF is a mild and efficient route for selective incorporation of fluoride ion into allylic systems. We herein describe the asymmetric fluorination of racemic, secondary allylic electrophiles with Et3N·3HF using a chiral-diene-ligated Ir complex. The methodology enables the formation of acyclic fluorine-containing compounds in good yields with excellent levels of asymmetric induction and overcomes the limitations previously associated with the enantioselective construction of secondary allylic fluorides bearing α-linear substituents.


  • Rhodium-catalyzed benzylic fluorination of trichloroacetimidates

    by Qi Zhang, Jason C. Mixdorf, Gilbert J. Reynders, Hien M. Nguyen